Market Research Report
Global Custom Antibody Services Market - 2021-2028
|Global Custom Antibody Services Market - 2021-2028|
Published: January 17, 2022
Content info: 180 Pages
Delivery time: 2 business days
Custom Antibody Services are a group of services that assist companies and organizations in developing antibodies for research, diagnostics, and therapeutics.
The global custom antibody services market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
ProSci Incorporated is a San Diego, California-based biotechnology firm specializing in research antibody products and custom antibody services and conducting research and development of neutralizing antibodies against HIV-1 and other emerging viruses. Cancer biomarker identification and neutralizing antibody creation against emerging viruses like HIV and influenza are among ProSci's research priorities.
Moreover, the National Institutes of Health (NIH) has awarded ProSci several Small Business Innovative Research (SBIR) grants for its innovative approach research using genetically engineered yeast strains and glycoproteins to mimic the HIV-1 glycan coat develop neutralizing antibodies against HIV-1 glycans. Its research initiatives have resulted in an invention patent and many peer-reviewed publications from the US Patent and Trademark Office. As a result, the market is likely to grow throughout the forecast period.
Antibodies are less likely to work for multiple applications. It takes a longer production time and costs high for developing antibodies. These are some of the factors the market is expected to get hampered in the forecast period.
The COVID-19 pandemic has moderately impacted healthcare systems and the market. Hundreds of antibodies in the form of polyclonal antibodies, monoclonal antibodies, and cocktail antibodies have been produced for treating COVID-19 in the preclinical and clinical stages. The US Food and Drug Administration (FDA) has approved four medicines for emergency usage, including convalescent plasma, bamlanivimab, REGN-Cov2, and a mixture of bamlanivimab and etesevimab. Hundreds of relevant clinical trials are currently underway around the world.
Moreover, Numerous research facilities implemented protocols limiting the number of lab employees allowed on-site to reduce the risk of virus transmission, putting many investigations on hold. The epidemic has had little impact on research initiatives funded by government expenditures, while several projects supported by private charities are experiencing financing shortfalls. COVID-19 has resulted in a significant reduction in donations to cancer-related charitable groups. For instance, the American Cancer Society predicts a $200 million drop in donations this year and has not accepted research funding applications for the Fall grant season. Thus, the market will undergo impetus growth during the forecast period.
The polyclonal segment accounted for the largest market share in 2020. Polyclonal antibodies are made up of a variety of distinct antibody molecules that all bind to the same antigen. Humans, other mammals, and certain plants all have them. Polyclonal antibodies are a combination of monoclonal antibodies that can be used to target numerous locations. They bind to the target molecule in many places. For instance, polyclonal antibodies are the best choice for an immune response to HIV/AIDS or Ebola virus infection since they are made up of several antibodies that target multiple locations in the complete protein. Therefore, vaccines play a major role in fighting a wide spectrum of viruses and bacteria.
In 2020, North America accounted for the highest revenue share. Increasing research activity and investment, quality concerns about catalog antibodies, novel techniques developed by the market players, rising antibody therapeutics and expanding drug pipelines, and developing industry-academic collaborations are factors the market is expected to boost in the forecast period. For instance, GenScript launched MonoRab, a tailored rabbit monoclonal antibody (mAB) service, in June 2021 has been included in the company's portfolio of comprehensive premium antibody services. MonoRab is a company-developed technique that combines hybridoma and early-stage monoclonal antibody sequencing. Both processes produce bespoke rabbit mAbs that are more specific, have a greater affinity, and have a wider variety of abilities, making them suitable for a wide range of applications. Moreover, Morphic Therapeutic, a biotechnology startup, partnered with Johnson & Johnson Private Limited's Janssen Pharmaceutical, Inc. in January 2021 to develop innovative antibodies targeting third integrin target proteins (a family of ubiquitous receptors). Therefore, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Major key players in the custom antibody services market are: R&D Systems, Inc., Thermo Fisher Scientific Inc., GenScript, Bio-Rad Laboratories, Inc., Sino Biological Inc. , Boster Biological Technology, RayBiotech Life, Inc., Bio-Techne, Elabscience Biotechnology Inc. and Biocompare. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which contribute to the growth of custom antibody services market. For instance, Y-Biologics, a South Korean firm, and Pierre Fabre, a French firm, announced a strategic Research Collaboration & Optional License Agreement to explore immune-oncology targets in March 2021. Y-monoclonal Biologic's antibodies have been tested against the first tumor by the corporations.
Bio-Rad Laboratories, Inc. is an American company that continued to produce innovative and useful products in the healthcare industry. Its products essentially include instruments, software, consumables, reagents, and content for the areas of cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education. These products are based on technologies to separate, purify, identify, analyze, and amplify biological materials such as antibodies, proteins, nucleic acids, cells, and bacteria.
HuCAL PLATINUM: The HuCAL PLATINUM phage library contains more than 45 billion functional human antibody genes in a Fab format. It has been designed to cover the human antibody diversity, to be flexible for further engineering and to yield antibodies with high expression titers.
The global custom antibody services market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.
LIST NOT EXHAUSTIVE